Oruka Therapeutics Overview
Oruka Therapeutics Target Price
Analysts' average 12-month price target for Oruka Therapeutics is $160.
Get informed when a big investor buys or sells
+ FollowShare Price
$92.51
Average Target Price
$155.00
67.5% upside
67.5% upside2 analysts in the last 4 months
High: $180 | Low: $130
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-07-01 | UBS | $130 | 40.5% upside |  |
| 2026-06-02 | Piper SandlerYasmeen Rahimi | $180 | 94.6% upside | |
| 2026-04-30 | Leerink Partners | $120 | 29.7% upside | |
| 2026-04-29 | H.C. Wainwright | $120 | 29.7% upside | |
| 2026-04-28 | UBS | $100 | 8.1% upside | |
| 2026-04-27 | BTIG | $151 | 63.2% upside | |
| 2026-04-27 | Wedbush | $165 | 78.4% upside | |
| 2026-04-27 | BarclaysEtzer Darout | $160 | 73% upside | |
| 2026-04-27 | Guggenheim | $200 | 116.2% upside | |
| 2026-04-15 | Wedbush | $85 |  8.1% downside | |
| 2026-03-13 | BTIGJulian Harrison | $73 | 21.1% downside | |
| 2026-01-13 | Wedbush | $45 | 51.4% downside | |
| 2026-01-07 | UBSMichael Yee | $50 | 46% downside | |
| 2025-12-18 | Piper Sandler | $75 | 18.9% downside | |
| 2025-10-27 | Guggenheim | $60 | 35.1% downside | |
| 2025-10-27 | H.C. WainwrightMitchell Kapoor | $40 | 56.8% downside | |
| 2025-10-13 | Barclays | $48 | 48.1% downside | |
| 2025-02-04 | Wolfe ResearchAndy Chen | $20 | 78.4% downside | |
| 2024-09-12 | JefferiesMichael Yee | $40 | 56.8% downside | |
| 2024-09-04 | WedbushDavid Nierengarten | $40 | 56.8% downside | |